Heightened self-efficacy for symptom management in patients with hematologic cancers prior to undergoing stem cell transplant may be used in improving symptom management and outcomes.
The US Food and Drug Administration has approved a 4-week dosing schedule for a commonly used cancer therapy.
Limited evidence exists that supports the use of most circulating tumor DNA assays in the diagnosis or management of early-stage or advanced solid tumors, according to an expert review.
Research presented at the 2018 BMT Tandem Meetings showed that potential role of immune checkpoint inhibitors in the post-transplant setting for patients with relapsed or large B-cell lymphomas.
CAR T-cell therapy may compliment HSCT for improving survival in ALL without increasing the risk of severe graft-versus-host disease, according to research presented at the 2018 BMT Tandem Meetings.
A recent study compared the effects of a collaborative care intervention vs usual care on health status of patients with chronic heart failure.
The NCCN has selected Envision's medical affairs platform to help manage proposals and investigator-initiated clinical trials in an effort to improve patient quality of life and reduce cancer-related deaths.
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.